{"id":51328,"date":"2017-12-04T12:59:27","date_gmt":"2017-12-04T12:59:27","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=51328"},"modified":"2022-11-30T11:15:24","modified_gmt":"2022-11-30T16:15:24","slug":"should-i-be-using-the-new-dot-custody-and-control-form","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/should-i-be-using-the-new-dot-custody-and-control-form\/","title":{"rendered":"Should I be Using the New DOT Custody and Control Form?"},"content":{"rendered":"\n<p>The Office of Management and Budget (OMB) recently approved a revised Federal Drug Testing Custody and Control Form (CCF).&nbsp; The revised CCF can be viewed at:&nbsp;<a href=\"http:\/\/www.reginfo.gov\/public\/do\/DownloadDocument?objectID=73335901\" target=\"_blank\" rel=\"noopener noreferrer\">http:\/\/www.reginfo.gov\/public\/do\/DownloadDocument?objectID=73335901<\/a><\/p>\n\n\n\n<p>There have been numerous questions about this new form. Here are a few of the most common:<\/p>\n\n\n\n<p><strong>When can I begin using the revised CCF?<\/strong><\/p>\n\n\n\n<ul>\n<li><a href=\"https:\/\/www.nationaldrugscreening.com\/dot-drug-test\/\"><strong>DOT-regulated employers<\/strong><\/a> and their service agents (collectors, laboratories, <strong><a href=\"https:\/\/www.nationaldrugscreening.com\/mro-service\/\">Medical Review Officers (MRO<\/a><\/strong>)) are authorized to use the revised CCF beginning January 1, 2018.<\/li>\n\n\n\n<li>As a laboratory, to avoid confusion about opioids testing prior to January 1, 2018&nbsp;for DOT-regulated clients, and to allow you to deplete your existing supplies of old CCF\u2019s, we recommend as a best practice, that you not mail any revised CCFs to your DOT-regulated clients or their service agents until after January 1, 2018.<\/li>\n<\/ul>\n\n\n\n<p><strong>How will I know the difference between the revised and \u2018old\u2019 CCF<\/strong>?<\/p>\n\n\n\n<p>The \u2018old\u2019 CCF is the one that has been used under the DOT-regulated program since 2010.<\/p>\n\n\n\n<p>The revised CCF includes the following changes:<\/p>\n\n\n\n<ul>\n<li><strong>In Step 1D:<\/strong>\n<ul>\n<li>Removal of the checkbox, the letters \u201cDOT\u201d and hash line in front of the text \u201cSpecify DOT Agency\u201d<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>In Step 5A:<\/strong>\n<ul>\n<li>Addition of four new analytes: oxycodone (OXYC), oxymorphone (OXYM), hydrocodone (HYC), and hydromorphone (HYM),<\/li>\n\n\n\n<li>Removal of the analyte methylenedioxyethylamphetamine (MDEA).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p><strong>After January 1, 2018, can the \u2018old\u2019 CCF still be used?<\/strong><\/p>\n\n\n\n<ul>\n<li>Yes, you may choose to use, the \u2018old\u2019 CCF until June 30, 2018.&nbsp; When using the \u2018old\u2019 CCF between January 1, 2018, and June 30, 2018, a \u2018memorandum for the record\u2019 is NOT required.&nbsp; After June 30, 2018, if you use the \u2018old\u2019 CCF, you must complete a \u2018memorandum for the record\u2019 per \u00a740.205(b)(2).<\/li>\n\n\n\n<li>After January 1, 2018, you may begin using the revised CCF.&nbsp; However, after June 30, 2018, you are&nbsp;<strong><em>required<\/em>&nbsp;<\/strong>to use the revised CCF.<\/li>\n<\/ul>\n\n\n\n<p>You can read the DOT Notice here:&nbsp;<a href=\"https:\/\/www.transportation.gov\/odapc\/Notice_CCF_December_2017%20\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.transportation.gov\/odapc\/Notice_CCF_December_2017&nbsp;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Office of Management and Budget (OMB) recently approved a revised Federal Drug Testing Custody and Control Form (CCF).&nbsp; The revised CCF can be viewed at:&nbsp;http:\/\/www.reginfo.gov\/public\/do\/DownloadDocument?objectID=73335901 There have been numerous questions about this new form. Here are a few of the most common: When can I begin using the revised CCF? How will I know [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":53349,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"50938,51052,55885,51324,51346,51327","_relevanssi_noindex_reason":"","footnotes":""},"categories":[45],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51328"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=51328"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/53349"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=51328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=51328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=51328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}